newsfilter
← Latest News
PR Newswire·

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

ICCM
  • IceCure Medical Ltd. (Nasdaq: ICCM) entered securities purchase agreements to sell 8,000,000 ordinary shares at $0.50 per share in a registered direct offering.
  • Gross proceeds from the share sale are expected to be approximately $4.0 million before fees & expenses.
  • A concurrent private placement involves issuing unregistered Series B Warrants for up to 8,000,000 shares & Series C Warrants for up to 8,000,000 shares.
  • All Warrants carry an exercise price of $0.55 per share & are exercisable immediately upon issuance.
  • Series B Warrants expire five years after issuance, while Series C Warrants expire one year after issuance.
  • The offering is expected to close on or about March 27, 2026, subject to customary conditions.
  • Net proceeds will be used for working capital & other general corporate purposes.
  • A.G.P./Alliance Global Partners is acting as the sole placement agent.
  • The shares are offered pursuant to an effective shelf registration statement on Form F-3 declared by the SEC on March 24, 2026.
  • The Warrants & underlying shares are issued under an exemption from registration under Section 4(a)(2) of the Securities Act & Regulation D.